Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
What's your choice of next line therapy for a metastatic papillary RCC who has progressed on cabozantinib?
Answer from: Medical Oncologist at Community Practice
Combination immunotherapy works well.
Sign In
or
Register
to read more
15923
Related Questions
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
How do you manage critically ill poor risk mixed germ cell tumor patients presenting de novo with extensive lung metastases and severe respiratory failure?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
Based on the results of the BladderPath trial, are you considering multiparametric bladder MRI for all patients with suspected bladder cancer diagnosis prior to TURBT, or for select patients only?
Is there any evidence for combining surgery and XRT +/- ADT for treatment of localized high risk prostate cancer?
When do you recommend incorporating HER2 testing into the diagnostic pathway for tumor types where HER2 overexpression is not commonly assessed?
How do you manage recurrent asymptomatic transaminitis from VEGF TKI in a patient renal cell carcinoma who needs drug to control disease?
How do you decide between radioligand therapy or cytotoxic chemotherapy in patients with metastatic castration-resistant prostate cancer with prior ARPI exposure who have cancer-related anemia?
How would do manage stage II/III Muscle invasive bladder cancer with large cell neuroendocrine histology?